Skip links

Confirm thalassemia diagnosis with region-tailored assays, and identify β-thalassemia modifiers.

Thalassemias are characterized by inherited defective hemoglobin synthesis leading to microcytic, hemolytic anemias. The clinical heterogeneity ranges from asymptomatic to very severe forms requiring regular blood transfusions. Globin StripAssays® detect common thalassemia-causing genetic variants worldwide, and the β-Thal Modifier StripAssay® identifies co-inherited variants known to ameliorate severity of beta-thalassemia.

Thalassemia

  • Severe thalassemia is life-limiting and poses a major public health burden in Mediterranean countries, Africa, the Middle East, South-East Asia, and the Indian subcontinent.
  • Mutations in the alpha- and beta-globin genes lead to reduced or abolished globin-chain synthesis or cause structurally abnormal hemoglobin.
  • Genetic analysis is required to confirm the clinical diagnosis and is indispensable for genetic counseling.
  • Apart from bone marrow transplantation, no ultimate cure is available up-to-date. However, identifying favorable genetic modifiers in patients help to predict the severity of beta-thalassemia phenotypes.

Products

Name REF Unit Size IFU Brochure
α-Globin StripAssay® 4-160 10 tests
PDF

PDF
β-Globin StripAssay® MED 4-130 20 tests
PDF

PDF
β-Globin StripAssay® IME 4-140 20 tests
PDF

PDF
β-Globin StripAssay® SEA 4-150 20 tests
PDF

PDF
β-Thal Modifier StripAssay® 4-170 20 tests
PDF

PDF
This website uses cookies to improve your web experience.
View
Drag